Core Insights - CapsoVision, Inc. announced a $14 million private placement in public equity financing to support its growth and product development [1][2][4] - The company reported preliminary, unaudited financial results for Q4 and full year 2025, with revenues of $3.9 million for Q4 and $13.6 million for the full year [5][7] Financing Details - The private placement involved the sale of 2,867,089 shares at a price of $4.883 per share, reflecting a 5% discount to the closing price on March 16, 2026 [2][3] - The proceeds from the financing will be allocated for general corporate purposes, including sales and marketing, research and development, and working capital [2][4] Financial Performance - For the fourth quarter of 2025, CapsoVision generated revenue of $3.9 million, while the total revenue for the full year reached $13.6 million [5][7] - As of December 31, 2025, the company had approximately $10.1 million in cash, cash equivalents, restricted cash, and investments [7] Product Development - CapsoVision is focused on advancing its product pipeline, including CapsoCam Colon and CapsoCam UGI, with enhanced AI capabilities aimed at improving gastrointestinal disease detection [4][6] - The company aims to transform the detection and screening of gastrointestinal diseases through its innovative imaging and AI-enabled solutions [6]

Core Insights - CapsoVision, Inc. is participating in the 38th Annual ROTH Conference on March 23, 2026, with key executives attending [1][2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis [3] - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [3] - The upcoming product, CapsoCam Colon™, features enhanced AI for non-invasive colon imaging and polyp detection, with plans to expand into other GI indications [3]

Core Viewpoint - CapsoVision, Inc. is set to release its third quarter 2025 financial results on November 13, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Group 1: Financial Results Announcement - The company will announce its third quarter 2025 financial results after the market closes on November 13, 2025 [1]. - A conference call and live webcast will take place on the same day at 1:30 pm PT / 4:30 pm ET to discuss the results [1]. Group 2: Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis [3]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [3]. - The upcoming product, CapsoCam Colon, features enhanced AI for non-invasive colon imaging and polyp detection [3]. - The company aims to expand its proprietary platform across multiple gastrointestinal indications, including esophageal and pancreatic disorders [3].

Core Viewpoint - CapsoVision, Inc. is actively participating in the 4th Annual ROTH Healthcare Opportunities Conference, highlighting its focus on advanced imaging and AI-enabled capsule endoscopy solutions [1] Company Overview - CapsoVision is a commercial-stage medical technology company dedicated to transforming the detection and diagnosis of gastrointestinal diseases through advanced imaging and AI solutions [3] - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel and supports cloud-based or direct video retrieval [3] - The upcoming product, CapsoCam Colon, features enhanced AI capabilities aimed at non-invasive colon imaging and polyp detection [3] - The company is developing a proprietary platform intended to expand across various gastrointestinal indications, including esophageal and pancreatic disorders [3]